CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara; Eileen M. O’Reilly; Gauri R. Varadhachary; Robert A. Wolff; Zev A. Wainberg; Andrew H. Ko; George A. Fisher; Osama E. Rahma; Jaclyn P. Lyman; Christopher R. Cabanski; Rosemarie Mick; Pier Federico Gherardini; Lacey J. Kitch; Jingying Xu; Theresa Samuel; Joyson Karakunnel; Justin Fairchild; Samantha Bucktrout; Theresa LaVallee; Cheryl Selinsky; Jacob E. Till; Erica L. Carpenter; Cécile Alanio; Katelyn T. Byrne; Richard O Chen; Ovid Trifan; Ute Dugan; Christine E. Horak; Vanessa M. Hubbard-Lucey; E. John Wherry; Ramy Ibrahim; Robert H. Vonderheide

doi:10.1016/s1470-2045(20)30532-5

CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

Mark H. O’Hara(University of Pennsylvania), Eileen M. O’Reilly(Memorial Sloan Kettering Cancer Center), Gauri R. Varadhachary(The University of Texas MD Anderson Cancer Center), Robert A. Wolff(The University of Texas MD Anderson Cancer Center), Zev A. Wainberg(University of California, Los Angeles), Andrew H. Ko(University of California, San Francisco), George A. Fisher(Stanford University), Osama E. Rahma(Dana-Farber Cancer Institute), Jaclyn P. Lyman(Parker Institute for Cancer Immunotherapy), Christopher R. Cabanski(Parker Institute for Cancer Immunotherapy), Rosemarie Mick(University of Pennsylvania), Pier Federico Gherardini(Parker Institute for Cancer Immunotherapy), Lacey J. Kitch(Parker Institute for Cancer Immunotherapy), Jingying Xu(Parker Institute for Cancer Immunotherapy), Theresa Samuel(Parker Institute for Cancer Immunotherapy), Joyson Karakunnel(Parker Institute for Cancer Immunotherapy), Justin Fairchild(Parker Institute for Cancer Immunotherapy), Samantha Bucktrout(Parker Institute for Cancer Immunotherapy), Theresa LaVallee(Parker Institute for Cancer Immunotherapy), Cheryl Selinsky(Parker Institute for Cancer Immunotherapy), Jacob E. Till(University of Pennsylvania), Erica L. Carpenter(University of Pennsylvania), Cécile Alanio(Parker Institute for Cancer Immunotherapy), Katelyn T. Byrne(Parker Institute for Cancer Immunotherapy), Richard O Chen(Personalis (United States)), Ovid Trifan(Apexigen (United States)), Ute Dugan(Bristol-Myers Squibb (United States)), Christine E. Horak(Bristol-Myers Squibb (United States)), Vanessa M. Hubbard-Lucey(Cancer Research Institute), E. John Wherry(Parker Institute for Cancer Immunotherapy), Ramy Ibrahim(Parker Institute for Cancer Immunotherapy), Robert H. Vonderheide(Parker Institute for Cancer Immunotherapy)

The Lancet Oncology

December 30, 2020

10.1016/s1470-2045(20)30532-5

Cited by 300

Abstract

Related Papers

No related papers found

Powered by citation graph analysis